Literature DB >> 20729760

A neurodevelopmental survey of Angelman syndrome with genotype-phenotype correlations.

Jennifer K Gentile1, Wen-Hann Tan, Lucia T Horowitz, Carlos A Bacino, Steven A Skinner, Rene Barbieri-Welge, Astrid Bauer-Carlin, Arthur L Beaudet, Terry Jo Bichell, Hye-Seung Lee, Trilochan Sahoo, Susan E Waisbren, Lynne M Bird, Sarika U Peters.   

Abstract

OBJECTIVE: Angelman syndrome (AS) is a neurodevelopmental disorder caused by a deletion on chromosome 15, uniparental disomy, imprinting defect, or UBE3A mutation. It is characterized by intellectual disability with minimal speech and certain behavioral characteristics. We used standardized measures to characterize the developmental profile and to analyze genotype-phenotype correlations in AS.
METHOD: The study population consisted of 92 children, between 5 months and 5 years of age, enrolled in a Natural History Study. Each participant was evaluated using the Bayley Scales of Infant and Toddler Development, Third Edition (BSID-III), the Vineland Adaptive Behavior Scales, Second Edition (VABS-II), and the Aberrant Behavior Checklist.
RESULTS: Seventy-four percent had a deletion and 26% had uniparental disomy, an imprinting defect or a UBE3A mutation ("non-deletion"). The mean +/- standard deviation BSID-III cognitive scale developmental quotient (DQ) was 40.5 +/- 15.5. Participants with deletions were more developmentally delayed than the non-deletion participants in all BSID-III domains except in expressive language skills. The cognitive DQ was higher than the DQ in each of the other domains, and the receptive language DQ was higher than the expressive language DQ. In the [ corrected] VABS-II, deletion participants had weaker motor and language skills than the non-deletion participants.
CONCLUSION: Children with AS have a distinct developmental and behavioral profile; their cognitive skills are stronger than their language and motor skills, and their receptive language skills are stronger than expressive language skills. Developmental outcomes are associated with genotype, with deletion patients having worse outcomes than non-deletion patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20729760      PMCID: PMC2997715          DOI: 10.1097/DBP.0b013e3181ee408e

Source DB:  PubMed          Journal:  J Dev Behav Pediatr        ISSN: 0196-206X            Impact factor:   2.225


  35 in total

1.  Microarray based comparative genomic hybridization testing in deletion bearing patients with Angelman syndrome: genotype-phenotype correlations.

Authors:  T Sahoo; S U Peters; N S Madduri; D G Glaze; J R German; L M Bird; R Barbieri-Welge; T J Bichell; A L Beaudet; C A Bacino
Journal:  J Med Genet       Date:  2005-09-23       Impact factor: 6.318

2.  Distinct phenotypes distinguish the molecular classes of Angelman syndrome.

Authors:  A C Lossie; M M Whitney; D Amidon; H J Dong; P Chen; D Theriaque; A Hutson; R D Nicholls; R T Zori; C A Williams; D J Driscoll
Journal:  J Med Genet       Date:  2001-12       Impact factor: 6.318

3.  Clinical, cytogenetic, and molecular diagnosis of Angelman syndrome: estimated prevalence rate in a Danish county.

Authors:  M B Petersen; K Brøndum-Nielsen; L K Hansen; K Wulff
Journal:  Am J Med Genet       Date:  1995-06-19

Review 4.  Behaviour problems in Angelman syndrome.

Authors:  J A Summers; D B Allison; P S Lynch; L Sandler
Journal:  J Intellect Disabil Res       Date:  1995-04

5.  Profiles and development of adaptive behavior in children with Down syndrome.

Authors:  E M Dykens; R M Hodapp; D W Evans
Journal:  Am J Ment Retard       Date:  1994-03

6.  Imprinted expression of the murine Angelman syndrome gene, Ube3a, in hippocampal and Purkinje neurons.

Authors:  U Albrecht; J S Sutcliffe; B M Cattanach; C V Beechey; D Armstrong; G Eichele; A L Beaudet
Journal:  Nat Genet       Date:  1997-09       Impact factor: 38.330

7.  Trajectories and predictors of the development of very young boys with fragile X syndrome.

Authors:  Jane E Roberts; Jean B Mankowski; John Sideris; Barbara Davis Goldman; Deborah D Hatton; Penny L Mirrett; Grace T Baranek; J Steven Reznick; Anna C J Long; Donald B Bailey
Journal:  J Pediatr Psychol       Date:  2008-12-12

8.  Predicting developmental outcome at school age from infant tests of normal, at-risk and retarded infants.

Authors:  R H Largo; S Graf; S Kundu; U Hunziker; L Molinari
Journal:  Dev Med Child Neurol       Date:  1990-01       Impact factor: 5.449

9.  Angelman syndrome: are the estimates too low?

Authors:  R H Buckley; N Dinno; P Weber
Journal:  Am J Med Genet       Date:  1998-12-04

10.  A solution to limitations of cognitive testing in children with intellectual disabilities: the case of fragile X syndrome.

Authors:  David Hessl; Danh V Nguyen; Cherie Green; Alyssa Chavez; Flora Tassone; Randi J Hagerman; Damla Senturk; Andrea Schneider; Amy Lightbody; Allan L Reiss; Scott Hall
Journal:  J Neurodev Disord       Date:  2009-03       Impact factor: 4.025

View more
  44 in total

Review 1.  Angelman Syndrome.

Authors:  Seth S Margolis; Gabrielle L Sell; Mark A Zbinden; Lynne M Bird
Journal:  Neurotherapeutics       Date:  2015-07       Impact factor: 7.620

2.  Angelman syndrome: Mutations influence features in early childhood.

Authors:  Wen-Hann Tan; Carlos A Bacino; Steven A Skinner; Irina Anselm; Rene Barbieri-Welge; Astrid Bauer-Carlin; Arthur L Beaudet; Terry Jo Bichell; Jennifer K Gentile; Daniel G Glaze; Lucia T Horowitz; Sanjeev V Kothare; Hye-Seung Lee; Mark P Nespeca; Sarika U Peters; Trilochan Sahoo; Dean Sarco; Susan E Waisbren; Lynne M Bird
Journal:  Am J Med Genet A       Date:  2011-01       Impact factor: 2.802

3.  A randomized controlled trial of levodopa in patients with Angelman syndrome.

Authors:  Wen-Hann Tan; Lynne M Bird; Anjali Sadhwani; Rene L Barbieri-Welge; Steven A Skinner; Lucia T Horowitz; Carlos A Bacino; Lisa M Noll; Cary Fu; Rachel J Hundley; Logan K Wink; Craig A Erickson; Gregory N Barnes; Anne Slavotinek; Rita Jeremy; Alexander Rotenberg; Sanjeev V Kothare; Heather E Olson; Annapurna Poduri; Mark P Nespeca; Hillary C Chu; Jennifer M Willen; Kevin F Haas; Edwin J Weeber; Paul A Rufo
Journal:  Am J Med Genet A       Date:  2017-09-25       Impact factor: 2.802

4.  Influence of CHDs on psycho-social and neurodevelopmental outcomes in children with Down syndrome.

Authors:  Jeannie Visootsak; Lillie Huddleston; Allison Buterbaugh; Adrienne Perkins; Stephanie Sherman; Jessica Hunter
Journal:  Cardiol Young       Date:  2015-02-16       Impact factor: 1.093

5.  Validating and Applying the CSBS-ITC in Neurogenetic Syndromes.

Authors:  Lisa R Hamrick; Bridgette L Tonnsen
Journal:  Am J Intellect Dev Disabil       Date:  2019-05

6.  Behavioral deficits in an Angelman syndrome model: effects of genetic background and age.

Authors:  Hsien-Sung Huang; Andrew J Burns; Randal J Nonneman; Lorinda K Baker; Natallia V Riddick; Viktoriya D Nikolova; Thorfinn T Riday; Koji Yashiro; Benjamin D Philpot; Sheryl S Moy
Journal:  Behav Brain Res       Date:  2013-01-04       Impact factor: 3.332

7.  Allelic specificity of Ube3a expression in the mouse brain during postnatal development.

Authors:  Matthew C Judson; Jason O Sosa-Pagan; Wilmer A Del Cid; Ji Eun Han; Benjamin D Philpot
Journal:  J Comp Neurol       Date:  2014-06-01       Impact factor: 3.215

Review 8.  Genetic insights into the functional elements of language.

Authors:  Adam Szalontai; Katalin Csiszar
Journal:  Hum Genet       Date:  2013-06-08       Impact factor: 4.132

Review 9.  Prader-Willi, Angelman, and 15q11-q13 Duplication Syndromes.

Authors:  Louisa Kalsner; Stormy J Chamberlain
Journal:  Pediatr Clin North Am       Date:  2015-04-22       Impact factor: 3.278

Review 10.  Angelman syndrome - insights into a rare neurogenetic disorder.

Authors:  Karin Buiting; Charles Williams; Bernhard Horsthemke
Journal:  Nat Rev Neurol       Date:  2016-09-12       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.